MDKP 67b
Alternative Names: DIM-107; DM 107; hK2 inhibitors; MDPK-67-b; RIK-7Latest Information Update: 28 Sep 2024
At a glance
- Originator Med Discovery
- Developer Dermadis; Med Discovery; University of Zurich
- Class Antineoplastics; Antipsoriatics; Immunotherapies; Proteins; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Peptide hydrolase inhibitors; Serine endopeptidase inhibitors; Tissue kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Netherton Syndrome; Neutropenia; Prostate cancer; Psoriasis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Prostate-cancer(Metastatic disease, Neoadjuvant therapy) in Switzerland (Parenteral)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Prostate-cancer(In volunteers) in Switzerland (Parenteral, Infusion)
- 23 Sep 2010 Preclinical trials in Netherton Syndrome in France (Topical)